| Autor: |
Bray, Kathryn Y., Mariani, Christopher L., Early, Peter J., Muñana, Karen R., Olby, Natasha J. |
| Předmět: |
|
| Zdroj: |
Journal of Veterinary Internal Medicine; Jan2021, Vol. 35 Issue 1, p388-396, 9p |
| Abstrakt: |
Background: Midazolam delivered by continuous rate infusion (CRI) might be effective in dogs with cluster seizures (CS) or status epilepticus (SE). Objective: To describe the use and safety of midazolam CRI in dogs with CS or SE. Animals One‐hundred six client‐owned dogs presenting to a veterinary teaching hospital with CS or SE. Methods: Retrospective review of medical records for dogs with CS or SE treated with a midazolam CRI. Results: Seventy‐nine dogs presented with CS and 27 dogs had SE. Seizure control was achieved in 82/106 dogs (77.4%) receiving a midazolam CRI. The median dose associated with seizure control was 0.3 mg/kg/h (range, 0.1‐2.5 mg/kg/h). The median duration of CRI was 25 hours (range, 2‐96 hours). Seizures were controlled in 34/40 dogs (85%) with idiopathic epilepsy, 32/43 dogs (74%) with structural epilepsy, 12/16 dogs (75%) with unknown epilepsy, and 4/7 dogs (57%) with reactive seizures (P =.20). Seizure control was achieved in 81% of dogs with CS and 67% in dogs with SE (P =.18). Dogs with idiopathic/unknown epilepsy were more likely to survive than those with structural epilepsy (87% vs 63%, P =.009). Adverse effects were reported in 24 dogs (22.6%) and were mild in all cases. Conclusions and Clinical Importance: Midazolam CRI is apparently safe and might be an effective treatment in dogs with CS or SE. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text